59 results about "Red Blood Cell Count" patented technology

Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.

The invention relates to methods and compounds for treating anemia of cancer. In particular, methods for treating anemia of cancer in a subject having cancer, and methods for increasing reticulocytes, increasing hemoglobin, increasing hematocrit, and increasing red blood cell count in subjects having anemia of cancer, wherein such subjects are refractory to treatment with recombinant human erythropoietin (EPO) are encompassed herein.

A novel reagent system for use with automated and semi-automated hematology analyzers including an essentially isotonic blood diluting reagent, a blood cell lysing and hemoglobin conversion reagent, and a second lysing reagent for differentiating white blood cells into classes by size and functional characteristics. The diluent reagent enhances properties for counting and sizing blood specimens, while stabilizing cellular volume and cellular integrity for many hours. The blood cell lysing reagent removes red blood cells and enables subsequent enumeration of white blood cells and simultaneous determination of hemoglobin without use of the toxic cyanide anion. The third lysing reagent and a companion quenching differentiates blood cells into classes by size and functional characteristics, based on d.c. impedance volume, conductivity/opacity and light scatter measurements. The companion quenching reagent adjusts pH and conductivity of the final measurement solution to match the analyzer system requirements. Novel methods for use of the reagents with automated and semi-automated hematology analyzers are also provided.</PTEXT>

Blood flow rates can be calculated using diffuse speckle contrast analysis in spatial and time domains. In the spatial domain analysis, a multi-pixel image sensor can be used to detect a spatial distribution of speckles in a sample caused by diffusion of light from a coherent light source that is blurred due to the movement of scatterers within the sample (e.g., red blood cells moving within a tissue sample). Statistical analysis of the spatial distribution can be used to calculate blood flow. In the time domain analysis, a slow counter can be used to obtain time-series fluctuations in light intensity in a sample caused by diffusion of light in the sample that is smoothened due to the movement of scatterers. Statistical analysis of the time-series data can be used to calculate blood flow.

Use of lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof and at least one anti-tumour food factor selected from soy protein and vitamin D inhibits tumour formation or growth, maintains or improves one or both of the white blood cell count and red blood cell count, stimulates the immune system, and/or treats or prevents cancer. Dietary (foods or food supplements), nutraceutical or pharmaceutical compositions may be used.

The present invention relates to administration of milk fat or a milk fat analogue, optionally with at least one additional therapeutic factor, preferably lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof, to inhibit tumour formation or growth, maintain or improve one or more of the white blood cell count, the red blood cell count, or the myeloid cell count, reduce cachexia, mucositis, and anemia, stimulate the immune system and treat or prevent cancer and the symptoms of cancer and side-effects of cancer therapies. The methods and medicinal uses of the invention may be carried out by employing dietary (as foods or food supplements), nutraceutical or pharmaceutical compositions. Compositions useful in the methods of the invention are also provided.

A single use, sterile, self-contained, compact, easy to use centrifugal separation unit provides for quick, reliable platelet concentration from whole blood. Anti-coagulated blood is injected through an elastomeric seal into a separation chamber featuring a tapered barrel and an end cap. At least one port is located in the end cap, at a desired radius from the longitudinal axis. The centrifugal field created by rotation of the chamber stratifies the blood radially, with red blood cells adjacent the wall of the barrel, and plasma found closest to the longitudinal axis. Opening the port causes the pressure of the centrifugal field to eject red blood cells or plasma, thereby increasing the concentration of platelets remaining in the chamber. After ceasing chamber rotation, the concentrated platelets are recovered.

The invention discloses a white blood cell classification reagent, which comprises the following raw materials: an ionic surfactant, a pH value adjusting buffer, an alkali metal salt for adjusting osmotic pressure, and an alcohol capable of dissolving and accelerating. According to the present invention, with the white blood cell classification reagent, white blood cells can be divided into four cell clusters, and the boundary between each cell cluster is clear; compared to the traditional five-class hemolytic agent, the white blood cell classification reagent of the present invention has thefollowing advantages that the boundary between the monocyte clusters and the neutrophil cluster is clear, and the clustering property is strong; the white blood cell classification reagent has characteristics of strong low-temperature hemolysis ability and wide temperature range, and can rapidly dissolve red blood cells in a low-temperature environment, ensure the normal classification of white blood cells, and reduce the manufacturing cost of the instrument on temperature control; and the white blood cell classification reagent further has advantages of low raw material cost, environmental protection and no toxicity, and can classify white blood cells by requiring only one reagent so as to achieve advantages of convenience, time saving and reduced production cost.

A blood analysis apparatus configured such that a nozzle sucks a predetermined amount of a blood specimen in a specimen container, and dispenses the specimen to each blood cell counting part which obtains count data, and a control part processes the count data to perform blood analysis. In this apparatus, two or more blood cell counting parts (basophil counting part, LMNE counting part, red blood cell counting part, white blood cell counting part) are constituted to obtain the count data of the same particular blood cell type (white blood cells), and the control part calculates the ratio or number of the existing blood cell from each count data, and judges whether the amount of the blood specimen sucked in the nozzle is normal or insufficient by comparing respective calculation results to determine whether they are within the predetermined allowable ranges.

The invention relates to a Chinese medicinal composition for relieving the hormone side effect of a western medicament when systemic lupus erythematosus (SLE) is treated. In the medicament, drying rehmannia root, mix-fried turtle shell, largetrifoliolious bugbane rhizome, spreading hedyotis herb, sweet wormwood herb, asiatic pennywort herb, red paeony root, fried coix seed, fingercitronsliced and raw liquoric root are combined, so that the Chinese medicinal composition can improve clinical symptoms of an SLE patient, contributes to raising the red blood cell count of the patient, lowers levels of triglyceride, cholesterol, erythrocyte sedimentation rate, urine protein and hematuresis of the SLE patient, reduces the using amount of the hormone, reduces the relapse rate, improves the overall curative effect, and can be combined with the western medicament to treat the systemic lupus erythematosus.

The invention discloses a ganoderma lucidum bran feed, which is prepared from the following raw materials in parts by weight: 10-20 parts of soybean, 15-30 parts of corn, 25-40 parts of wheat bran, 30-40 parts of rice bran and 3-6 parts of ganoderma lucidum strain. The feed is obtained by culturing and fermenting liquid ganoderma lucidum, so that the meat quality of the conventional domestic animals is achieved, and rich natural health-care factors such as ganoderma lucidum polysaccharides, karnosin and the like are contained simultaneously; ganoderma lucidum mycelia are rich in various pharmacological ingredients and organic germanium which has an anticancer function, so that the generation of interferon, the growth of interferon control cancel cells can be called, the oxygen carrying capacity of red blood cells is enhanced, metabolism is promoted, the organism immunity is enhanced, and the incidence rate is lowered; chemical substances such as mold preventing agents, antibiotics, hormones and the like are added into a formula, so that residue of toxic and harmful substances is avoided, the culturing process is simple and controllable, the culturing success rate is increased, the culturing period is shortened, and batch production is available; the feed has stable quality and low cost, and is suitable for culturing various animals; and the meat quality of cultured animals are enhanced, and most importantly, human body health is facilitated.

The present invention provides methods of treating diseases and disorders associated with aberrant erythropoiesis. Specifically, the present invention provides a method for treating polycythemia in a subject by administering an inhibitor of miR-451. Methods of increasing red blood cell count and treating anemia in a subject by administering miR-451 mimetics are also disclosed.

The invention provides a multifunctional blood detector. The multifunctional blood detector comprises a central processing unit, a blood collecting bottle energy heating and reagent bottle energy refrigerating stirring arm, a blood detection unit and a remote display device; the central processing unit has properties of an automatic controller and comprises a Bluetooth module, a wireless local area network, an alarming module, a fingerprint confirmation and storage module and a blood collecting needle, blood collecting bottle and reagent bottle holder for storing a blood collecting needle, a blood collecting bottle and a reagent bottle, blood is stirred and mixed to be uniform through the blood collecting bottle energy heating and reagent bottle energy refrigerating stirring arm, the blood detection unit comprises a CRP detection device, a red blood cell counting chamber, a hemoglobin detection device, a laser detection device and a blood reagent strip corresponding item detection position, and the remote display device is used for setting detection items including CRP detection, red cell counting, hemoglobin detection, laser detection and blood reagent strip corresponding item detection.

The invention discloses a Zhuang medicine composition assisted in resisting lung cancer. The Zhuang medicine composition is characterized by being prepared from the following Zhuang medicinal materials: Nyarinngoux (Chinese name: baihuasheshecao), Gaeubwnhgauh (Chinese name: baiying), Byaekloekhauj (Chinese name: longkui), Buenqcilienz (Chinese name: banzhilian), Ginghgun (Chinese name: guangxi eshu), Fouxndoengz (Chinese name: shishangbai), Swnjgyaeujhenj (Chinese name: huanghuadaoshuilian), Raggongox (Chinese name: lugen), GO gyauhgujlanz (Chinese name: jiaogulan) and Lozhangoj (Chinese name: luohanguo). The Zhuang medicine composition is combined with chemical drugs for curing lung cancer, can reduce the toxic and side effects of inappetence caused by the chemical drugs, reduce the damage of the chemical drugs to immune organs, increase white blood cell count, blood platelet count, red blood cell count and hemoglobin count to reduce the inhibiting effect on myelosuppression, reduce the content of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase to alleviate the damage to liver functions and increase the tumor suppression function of the chemical drugs. Namely, the Zhuang medicine composition is combined with the chemical drugs for curing the lung cancer and has the effects of toxicity reducing and efficacy enhancing.

The invention relates to a pink bottle liner, and in particular relates to a formula of the pink bottle liner. The formula of the pink bottle liner comprises the following components by weight percent: 39% to 41% of potash feldspar, 54% to 56% of borax and 1.5% to 2.0% of selenium powder. The pink bottle liner has the advantage of health-care effect, so as to satisfy the market requirement. By adding selenium elements into the bottle liner, when the bottle liner is used for storing water, a trace of selenium elements can be contained in the water, so that the immunity of a human body is improved. The pink bottle liner has the effects of oxidation resistance, senescence delaying, repair cell protection, diabetes treatment, cancer prevention and resistance, eye protection, improvement on the oxygen carrying capacity of red blood cells, prevention and treatment on cardiovascular and cerebrovascular diseases, detoxification, toxin prevention, pollution resistance and liver protection.